Details of Disease

General Information of Disease (ID: DISVYKGN)

• Disease Name: Skin infection
• Synonyms: skin infection
• Disease Class: 1F28-1G0Z: Skin and skin-structure infection
• Definition: An inflammatory process affecting the skin, caused by bacteria, viruses, parasites, or fungi. Examples of bacterial infection include carbuncles, furuncles, impetigo, erysipelas, and abscesses. Examples of viral infection include shingles, warts, molluscum contagiosum, and pityriasis rosea. Examples of parasitic infection include scabies and lice. Examples of fungal infection include athlete's foot, yeast infection, and ringworm.
• Disease Hierarchy:
  DISFDJN8: Skin disorder caused by infection
  DISY5SZC: Dermatitis
  DISEM33Q: Infectious disease
  DISVYKGN: Skin infection
• ICD Code:
  ICD-11: ICD-11: 1F28-1G0Z
  ICD-10: ICD-10: L00-L99
  ICD-9: ICD-9: 680-709
  Expand ICD-9: 6.81E+89
• Disease Identifiers:
  MONDO ID: MONDO_0021201
  MESH ID: D012874
  UMLS CUI: C0037278
  MedGen ID: 52365
  SNOMED CT ID: 108365000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 10 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bacitracin	DM5OHYE	Approved	Small molecular drug	[1]
Butenafine	DMOJ4ZI	Approved	Small molecular drug	[2]
Cetrimide	DMKRI2W	Approved	Small molecular drug	[3]
Daptomycin	DMFDQ3I	Approved	NA	[4]
Delafloxacin Meglumine	DMVTU5Q	Approved	Small molecular drug	[5]
Linezolid	DMGFPU2	Approved	Small molecular drug	[6]
Tedizolid	DMG2SKR	Approved	Small molecular drug	[3]
Teicoplanin	DMAQ2LK	Approved	Small molecular drug	[7]
Tigecycline	DMLE7IO	Approved	Small molecular drug	[8]
Vancomycin	DM3JFIH	Approved	NA	[9]

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lixivaptan	DMDN4ZP	Phase 3	Small molecular drug	[10]
TD-1792	DMGKBZH	Phase 3	Small molecular drug	[11]
BC-7013	DMMKCJ6	Phase 2	NA	[11]
Contezolid	DMZ0F65	Phase 2	NA	[11]
Cx-501	DMAAQKR	Phase 2	NA	[12]
ICX-RHY	DM191E8	Phase 2	NA	[13]
JB991	DMKU6MW	Phase 2	NA	[14]
R-salbutamol sulphate	DMGLCVU	Phase 2	NA	[15]
Avrina	DMRS58M	Phase 1/2	NA	[16]
S. epidermidis vaccine	DMVMAYI	Phase 1	NA	[17]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AVT-02 UE	DM8NA4M	Discontinued in Phase 2	NA	[18]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CHGN111	DMYSF86	Investigative	NA	[19]
HB-1275	DMP86Z1	Investigative	NA	[19]
MRLP-164	DMKL0OS	Investigative	NA	[19]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
• [2] Butenafine FDA Label
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Daptomycin FDA Label
• [5] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [6] Linezolid FDA Label
• [7] The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Expert Rev Anti Infect Ther. 2020 May;18(5):415-422.
• [8] Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110.
• [9] Vancomycin FDA Label
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020550)
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] ClinicalTrials.gov (NCT00987142) Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa. U.S. National Institutes of Health.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038677)
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025167)
• [15] ClinicalTrials.gov (NCT00625521) Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions. U.S. National Institutes of Health.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018437)
• [17] Staphylococcus aureus vaccine conjugate--Nabi: Nabi-StaphVAX, StaphVAX. Drugs R D. 2003;4(6):383-5.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025413)
• [19] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.